Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HX008 + OH2 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HX008 | HX-008|HX 008|Pucotenlimab | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | HX008 is a monoclonal antibody that binds to PD-1 (PDCD1) and blocks its interaction with PD-L1 (CD274) and PD-L2 (PDCD1LG2), inhibiting downstream signaling and potentially leading to activation of T-cell-mediated immune response against tumor cells and inhibition of tumor growth (PMID: 32106752). | |
OH2 | OH-2|OH 2|oHSV-2-expressing GM-CSF OH2 | OH2 is an oncolytic herpes simplex virus-2 (HSV-2) engineered to include deletions in the viral genes ICP34.5 and ICP47, and to express human granulocyte macrophage colony stimulating factor (GM-CSF), which may lead to the activation of anti-tumor immune response and tumor cell killing (PMID: 32055679, PMID: 29872496). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|